Allos Therapeutics Inc
(ALTH) 3.94

11080 Circlepoint Road Suite 200, Westminster, CO 80220

The Company develops and commercializes innovative small molecule drugs for improving cancer treatments. Small molecule drugs are non-protein products produced by chemical synthesis. The Company's lead product candidate is RSR13, a synthetic small molecule that increases the releases of oxygen from hemoglobin. The company is currently conducting clinical trials of RSR13. RSR13 is designed to mitigate the effects of tissue hypoxia. RSR13 can be used to improve existing treatments for cancer and treat many diseases attributed to or aggravated by tissue oxygen deprivation. RSR 13 has been administered safely to several hundred patients, most of whom were cancer patients receiving concurrent radiation therapy.

Array Biopharma Inc
(ARRY) 2.87

3200 Walnut Street, Boulder, CO 80301

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat debilitating and life-threatening diseases. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.

Cephalon Inc
(CEPH) 60.58

41 Moores Road, Frazer, PA 19355 4745 Wiley Post Way, Salt Lake City, UT 84116 20 rue Charles Martigny 94701 Maisons-Alfort CEDEX FRANCE

Launched in 1987 by an enthusiastic young researcher, Dr. Frank Baldino, Jr., Cephalon’s growth has led to discoveries and new therapies for sleep disorders, neurological diseases, cancer, pain management and addiction. The company’s early focus on neurodegenerative disease led to breakthroughs in understanding the chemistry of what causes cells to die, insights that are now being applied to treating cancer as well as diseases of the central nervous system. At the same time, the company explored unmet patient needs in sleep medicine, becoming the market leader in treating wakefulness (www.provigil.com) and developing the only FDA approved treatment for shift-work sleep disorder. Our gains in these areas have allowed Cephalon to branch out into some promising new fields. The company is applying its knowledge about cell and molecular biology to some promising early-stage research in new cancer therapies.

GlobeImmune, Inc.

1450 Infinite Drive, Louisville, Colorado 80027

GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of infectious diseases and cancer.

Myriad Genetics, Inc.
(MYGN) 15.88

320 Wakara Way, Salt Lake City, UT 84108

Myriad's is to develop novel healthcare products in areas of critical need and to address some of the most pervasive diseases of our time. We offer a range of cancer predictive medicine products and are developing therapeutics that include drug candidates in the areas of Alzheimer's disease and cancer.

NPS Pharmaceuticals
(NPSP) 6.40

Morris Corporate Center 1, 4th Floor, Building B, 300 Interpace Parkway, Parsippany, NJ 07054 383 Colorow Drive, Salt Lake City, UT 84108 30 College Street, Suite 301, Toronto, Ontario M5G 1K2 CANADA

NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervous system disorders.

OSI Pharmaceuticals, Inc
(OSIP) 0.00

41 Pinelawn Road, Melville, NY 11747 2860 Wilderness Place, Boulder, CO 80301 Watlington Road Oxford, OX4 6LT, UK

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms. Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K. subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases, particularly type 2 diabetes and obesity.

Pharmion Corporation
(PHRM) 0.00

2525 28th St., Suite 200, Boulder, CO 80301

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Qlt Inc.
(QLTI) 6.11

887 Great Northern Way, Vancouver, BC, Canada V5T 4T5 2579 Midpoint Drive, Fort Collins, CO 80525

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®.

Siga Technologies Inc
(SIGA) 7.70

420 Lexington Avenue, Suite 408, New York, NY 10170 4575 SW Research Way, Suite 230, Corvallis, OR 97333

SIGA is committed to the discovery, development and commercialization of novel products for the prevention and treatment of serious infectious diseases, including products for use in defense against biological warfare agents.

Somalogic

1775 38th Street Boulder, Colorado 80301

SomaLogic uses its unique aptamer array technology and bioinformatics capabilities to discover disease-specific biomarkers and protein signatures. Using a simple blood test, clinicians will have the information to transform medical practice and make a real difference in people's lives. The approach can be applied across a broad spectrum of clinical challenges faced by physicians. Proteins say a lot about a person, and SomaLogic is discovering what they say.

Tapestry Pharmaceuticals, Inc.
(TPPHQ.PK) 0.00

4840 Pearl East Circle, 300W, Boulder, CO 80301-2408

Tapestry Pharmaceuticals, Inc. is a company focused on developing proprietary therapies for the treatment of cancer. We are also actively engaged in evaluating new therapeutic agents and related technologies for in-licensing. Tapestry's technical expertise is our ability to identify, chemically alter and produce novel therapeutic compounds derived from natural product sources. Tapestry has developed a novel third generation taxane, TPI 287.